1. Researchers developed a two-in-one approach to generate non-viral, gene-specific targeted CAR-T cells through CRISPR–Cas9.
2. An innovative type of anti-CD19 CAR-T cell with PD1 integration was developed and showed superior ability to eradicate tumour cells in xenograft models.
3. In adoptive therapy for relapsed/refractory aggressive B cell non-Hodgkin lymphoma, high rate (87.5%) of complete remission and durable responses without serious adverse events were observed in eight patients.
The article is generally reliable and trustworthy as it provides detailed information on the research conducted by the authors, including the methods used, results obtained, and conclusions drawn from the study. The authors have also provided evidence to support their claims, such as single-cell analysis showing that the electroporation method resulted in a high percentage of memory T cells in infusion products, and PD1 interference enhanced anti-tumour immune functions. Furthermore, the article has been published in Nature which is a reputable journal with rigorous peer review process.
However, there are some potential biases that should be noted when assessing this article. Firstly, the authors have not explored any counterarguments or alternative approaches to their research which could provide further insights into their findings. Secondly, there is no mention of possible risks associated with using non-viral gene specific targeted CAR-T cells which could be important for readers to consider before making decisions based on this research. Finally, although the authors have provided evidence to support their claims, they have not presented both sides equally which could lead to one sided reporting of their findings.